Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines
- PMID: 29587412
- PMCID: PMC6027373
- DOI: 10.3390/vaccines6020017
Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines
Abstract
The National Institute of Allergy and Infectious Diseases recently published a strategic plan for the development of a universal influenza vaccine. This plan focuses on improving understanding of influenza infection, the development of influenza immunity, and rational design of new vaccines. Epidemiological studies such as prospective, longitudinal cohort studies are essential to the completion of these objectives. In this review, we discuss the contributions of epidemiological studies to our current knowledge of vaccines and correlates of immunity, and how they can contribute to the development and evaluation of the next generation of influenza vaccines. These studies have been critical in monitoring the effectiveness of current influenza vaccines, identifying issues such as low vaccine effectiveness, reduced effectiveness among those who receive repeated vaccination, and issues related to egg adaptation during the manufacturing process. Epidemiological studies have also identified population-level correlates of protection that can inform the design and development of next generation influenza vaccines. Going forward, there is an enduring need for epidemiological studies to continue advancing knowledge of correlates of protection and the development of immunity, to evaluate and monitor the effectiveness of next generation influenza vaccines, and to inform recommendations for their use.
Keywords: correlates of protection; epidemiology; hemagglutinin; influenza; influenza vaccines; neuraminidase.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Reed C., Chaves S.S., Daily Kirley P., Emerson R., Aragon D., Hancock E.B., Butler L., Baumbach J., Hollick G., Bennett N.M., et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0118369. - DOI - PMC - PubMed
-
- Ohmit S.E., Thompson M.G., Petrie J.G., Thaker S.N., Jackson M.L., Belongia E.A., Zimmerman R.K., Gaglani M., Lamerato L., Spencer S.M., et al. Influenza vaccine effectiveness in the 2011–2012 season: Protection against each circulating virus and the effect of prior vaccination on estimates. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2014;58:319–327. doi: 10.1093/cid/cit736. - DOI - PMC - PubMed
-
- McLean H.Q., Thompson M.G., Sundaram M.E., Kieke B.A., Gaglani M., Murthy K., Piedra P.A., Zimmerman R.K., Nowalk M.P., Raviotta J.M., et al. Influenza vaccine effectiveness in the United States during 2012–2013: Variable protection by age and virus type. J. Infect. Dis. 2015;211:1529–1540. doi: 10.1093/infdis/jiu647. - DOI - PMC - PubMed
-
- Zimmerman R.K., Nowalk M.P., Chung J., Jackson M.L., Jackson L.A., Petrie J.G., Monto A.S., McLean H.Q., Belongia E.A., Gaglani M., et al. 2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2016;63:1564–1573. doi: 10.1093/cid/ciw635. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
